🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

MCT Enteral Feeding to Reduce Chyle Leak After Oesophagectomy

RecruitingNAAges 18 Years - anyAllRoyal College of Surgeons, Ireland
NCT07616245 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Chyle leak (chylothorax) is a recognised complication following minimally invasive oesophagectomy for oesophageal cancer and may result in prolonged hospital stay, nutritional compromise, and need for additional interventions. Medium-chain triglyceride (MCT) feeds reduce lymphatic flow as they are absorbed directly via the portal circulation rather than through the thoracic duct. While MCT feeds are commonly used in the management of established chyle leaks, their role in prevention has not been evaluated in a randomised controlled trial. This single-centre randomised controlled trial will evaluate whether initiating postoperative jejunostomy feeding with MCT-based enteral nutrition reduces the incidence of clinically and biochemically confirmed chyle leak compared with standard enteral feeding in patients undergoing minimally invasive or robotic-assisted oesophagectomy. Participants

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of oesophageal cancer (adenocarcinoma or squamous cell carcinoma) * Planned minimally invasive or robotic-assisted oesophagectomy (MIO or RAMIO) with curative intent * Placement of feeding jejunostomy at or prior to oesophagectomy * Able to provide written informed consent Exclusion Criteria: * Inability to provide informed consent * No feeding jejunostomy placed at or prior to surgery * Prior or concomitant malignancy that would interfere with study protocol or outcomes
💊

What it tests

  • Standard Jejunostomy Feed (Nutrison Protein Plus)
  • MCT-Based Jejunostomy Feed (Nutrison Peptisorb)
📍

Where

1 site
Beaumont RCSI Cancer Centre
Beaumont, Ireland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy